Evaluation of the in vitro antimycobacterial activity of bioresorbable implants impregnated with silver nanoparticles and antimycobacterial drugs in the pulmonary tuberculosis treatment
Heading: Phthisiology Article type: Original article
Authors: Sinitsyn M.V., Tokaev T.K., Bikbaev A.S., Eliseev P.I., Zagoskin Yu.D., Grigoriev T.E.
Organization: Pirogov Russian National Research Medical University, Moscow, Russia , National Research Centre “Kurchatov Institute”, Moscow, Russia, National Medical Research Center for Phthisiopulmonology and Infectious Diseases, Moscow, Russia
Objective: to evaluate the antimycobacterial activity of implants based on polylactide (PLA), polycaprolactone (PCL), and chitosan impregnated with silver nanoparticles and antituberculosis drugs (ATDs). Material and methods. This in vitro study comprised two experiments, each performed in triplicate. Bioresorbable implants based on PLA/PCL and chitosan impregnated with silver nanoparticles, silver proteinate, or one of seven ATDs (delamanid, linezolid, bedaquiline, moxifoxacin, capreomycin, isoniazid, amikacin) were investigated. Antimycobacterial activity was assessed by agar difusion, BACTEC MGIT 960, and broth microdilution using the Mycobacterium tuberculosis H37Rv reference strain. Results. Silver nanoparticles at high concentration (0.034–0.042 nmol/mL) demonstrated bactericidal activity lasting 35 days. Silver proteinate showed only marginal inhibitory efect against M. tuberculosis, delaying culture growth by 5 days compared to the control. ATDs, with the exception of delamanid, were released within the frst 1–3 days and exhibited bactericidal activity against M. tuberculosis, after which antimycobacterial activity declined. Conclusion. Implants impregnated with silver nanoparticles provided a prolonged bactericidal efect against M. tuberculosis, which justifes the need for further investigation of these implants.
Bibliography:
1. Global tuberculosis report 2025. Geneva: World Health Organization; 2025.
2. Giller DB, Glotov EM, Kesaev OSh, et al. The surgical treatment of destructive pulmonary tuberculosis in patients with diabetes. Innovative Medicine of Kuban. 2020;17(1):16-22. DOI:10.35401/2500-0268-2020-17-1-16-22
3. Donchenko DV, Krasnikova EV, Salikhov BU, et al. The basics and prospects of surgical collapse treatment for advanced pulmonary tuberculosis. Vrach. 2023;34(3):25-32. DOI:10.29296/25877305-2023-03-05
4. Krasnikova EV, Bagirov MA, Lovacheva OV, et al. Efcacy of extrapleural plombage with silicone plug in destructive pulmonary tuberculosis patients and its impact on pulmonary functions and blood gases. Tuberculosis and Lung Diseases. 2019;97(3):16–25. DOI:10.21292/2075-1230-2019-97-3-16-25
5. Vasileva IA, Sevastianov VI, Tokaev KV, et al. In vivo assessment of the biocompatible properties of resorbable porous materials for pleural implantation. Russian Journal of Transplantology and Artifcial Organs. 2021;23(1):49-59 DOI:10.15825/1995-1191-2021-1-49-59
6. Wang W, Guo H, Lin S, et al. Biosafety materials for tuberculosis treatment. Biosaf Health. 2022;4(4):258-68. DOI:10.1016/j.bsheal.2022.03.013
7. Grigoriev TE, Bukharova TB, Vasilyev AV, et al. Efect of molecular characteristics and morphology on mechanical performance and biocompatibility of PLA-based spongious scafolds. BioNanoScience. 2018;8(4):977-83. DOI:10.1007/s12668-018-0557-9
8. Barua N, Buragohain AK. Therapeutic potential of silver nanoparticles (AgNPs) as an antimycobacterial agent: A comprehensive review. Antibiotics (Basel). 2024;13(11):1106. DOI:10.3390/antibiotics13111106
9. More PR, Pandit S, Filippis A, et al. Silver nanoparticles: Bactericidal and mechanistic approach against drug resistant pathogens. Microorganisms. 2023;11(2):369. DOI:10.3390/microorganisms11020369
10. Kim Y, Zharkinbekov Z, Raziyeva K, et al. Chitosan-based biomaterials for tissue regeneration. Pharmaceutics. 2023;15(3):807. DOI:10.3390/pharmaceutics15030807
11. Kazyulina AA, Gracheva AN, Tokaev TK, et al. Assessment of bactericidal efect of volume-porous composite materials impregnated with silver on Mycobacterium tuberculosis. Clinical Microbiology and Antimicrobial Chemotherapy. 2025;27(3):406-16. DOI: 10.36488/cmac.2025.3.406-416
12. Dartois VA, Rubin EJ. Anti-tuberculosis treatment strategies and drug development: Challenges and priorities. Nat Rev Microbiol. 2022;20(11):685-701. DOI:10.1038/s41579-022-00731-y
13. Cidade do Carmo C, Brito M, Oliveira JP, et al. Cellulose acetate and polycaprolactone fbre coatings on medical-grade metal substrates for controlled drug release. Polymers (Basel). 2024;16(14):2006. DOI:10.3390/polym16142006
14. Haroosh HJ, Dong Y, Jasim S, Ramakrishna S. Improvement of drug release and compatibility between hydrophilic drugs and hydrophobic nanofbrous composites. Materials (Basel). 2021;14(18):5344. DOI:10.3390/ma14185344
15. Caggiano NJ, Armstrong MS, Georgiou JS, et al. Formulation and scale-up of delamanid nanoparticles via emulsifcation for oral tuberculosis treatment. Mol Pharm. 2023;20(9):4546-58. DOI:10.1021/acs.molpharmaceut.3c00240
| Attachment | Size |
|---|---|
| 02_maket_211-216.pdf | 352.65 KB |



